Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The impact of viral etiology in yttrium-90–treated hepatocellular carcinoma.
Authors
Itamar Marie Naveh-Benjamin
University of Virginia, Charlottesville, VA;
Itamar Marie Naveh-Benjamin , Ruyun Jin , Kara D Romano , Tri Minh Le , Paul Raymond Kunk , Matthew Reilley , Paul Read , Einsley-Marie Janowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 608)
DOI
10.1200/JCO.2023.41.4_suppl.608
Abstract #
608
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.
First Author: Peter R. Galle
Poster
2014 Gastrointestinal Cancers Symposium
Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians.
First Author: Kit Man Wong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.
First Author: Timothy J. Brown
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).
First Author: Ashwin Somasundaram